Physician profile
John T Munshower
NPI 1871597534
$6,212.89
in general payments reported to CMS, 2019-2025
47 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,001 · 2020: $1,931 · 2021: $199 · 2022: $82.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $655.18 | 2019-2020 | |
| Ucb, INC. | $490.37 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $409.98 | 2019-2020 | |
| Genzyme Corporation | $333.18 | 2019-2020 | |
| Emd Serono, INC. | $273.15 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $270.89 | 2019-2020 | |
| Allergan, INC. | $262.32 | 2019-2022 | |
| Biogen, INC. | $254.83 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $247.59 | 2019-2022 | |
| Genentech USA, INC. | $230.72 | 2019-2020 | |
| Livanova USA, INC. | $197.10 | 2019-2020 | |
| Eisai INC. | $184.70 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $175.36 | 2019-2021 | |
| Acorda Therapeutics, INC | $161.97 | 2019-2021 | |
| Amgen INC. | $157.01 | 2019-2020 |
Show all 47 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Munshower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.